首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MDK |
| Uniprot No | P21741 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-143aa |
| 氨基酸序列 | VAKKKDKVKK GGPGSECAEW AWGPCTPSSK DCGVGFREGT CGAQTQRIRC RVPCNWKKEF GADCKYKFEN WGACDGGTGT KVRQGTLKKA RYNAQCQETI RVTKPCTPKT KAKAKAKKGK GKD |
| 预测分子量 | 13.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MDK(Midkine)重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: *Recombinant human midkine stimulates proliferation and migration of embryonic neuronal cells*
**作者**: Michikawa M, et al.
**摘要**: 本研究利用大肠杆菌表达系统成功制备了重组人源MDK蛋白，验证了其生物活性。实验表明，重组MDK能显著促进胚胎神经元细胞的增殖和迁移，提示其在神经发育或再生医学中的潜在应用价值。
---
2. **文献名称**: *Purification and functional characterization of recombinant midkine for cancer therapeutic studies*
**作者**: Shimizu T, et al.
**摘要**: 通过哺乳动物细胞表达系统纯化重组MDK蛋白，发现其能特异性结合肿瘤细胞表面受体(如ALK和LRP1)，激活下游促存活信号通路。研究为MDK在癌症靶向治疗中的药物开发提供了实验基础。
---
3. **文献名称**: *Role of recombinant midkine in inflammatory response modulation*
**作者**: Li Y, et al.
**摘要**: 该研究利用昆虫细胞表达系统生产高纯度重组MDK，证实其通过调控NF-κB通路抑制巨噬细胞的促炎因子释放，表明重组MDK可能作为炎症性疾病的新型治疗分子。
---
(注：以上文献信息为示例性质，实际引用需根据具体研究内容匹配真实发表的论文。)
Midkine (MDK), a heparin-binding growth factor, was initially identified in the early 1990s as a product of a retinoic acid-responsive gene during embryonic development. It belongs to a small protein family alongside pleiotrophin, sharing conserved structural motifs but distinct expression patterns. MDK plays critical roles in cell proliferation, survival, migration, and tissue repair, particularly during embryogenesis. However, its re-expression in adults is strongly associated with pathological conditions, including cancer progression, inflammatory diseases, and neurodegenerative disorders.
Structurally, MDK consists of two N-terminal domains rich in β-sheets, a flexible C-terminal domain, and multiple disulfide bonds stabilizing its tertiary structure. Recombinant MDK production typically employs bacterial (e.g., E. coli) or mammalian expression systems, followed by heparin-affinity chromatography purification to preserve its bioactive conformation. This engineered protein enables precise study of MDK's interactions with receptors like ALK, LRP1. and integrins, as well as its modulation of signaling pathways such as PI3K/AKT and MAPK.
In oncology, recombinant MDK serves as both a research tool and a therapeutic target. Its overexpression correlates with tumor angiogenesis, metastasis, and chemotherapy resistance in various cancers. Conversely, recombinant MDK-neutralizing antibodies or antisense oligonucleotides are being explored as anticancer strategies. Beyond cancer, it’s investigated for dual roles in neuroprotection and neurotoxicity, influencing conditions like Alzheimer’s disease and neural regeneration.
Current research leverages recombinant MDK to develop diagnostic biomarkers and targeted therapies, while its pleiotropic functions continue to reveal connections between developmental biology and disease mechanisms. Challenges remain in fully elucidating its context-dependent signaling and therapeutic potential.
×
